BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
|Target Hit|| Long (1Y)
Angel Broking maintains buy on Cadila Healthcare
Cadila Healthcare's formulation business registered de-growth of 4 per cent in Q3 but its other businesses reported 16 per cent growth in revenue. The brokerage continued to maintain "buy" rating on the stock.